Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled Iloprost in HFpEF (ILO-HOPE)
NCT03620526Phase 4Unknown
- Sponsor
- National Taiwan University Hospital
- Start
- Nov 2017
- Primary completion
- Jan 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of iloprost in heart failure with preserved ejection fraction (HFpEF), sponsored by National Taiwan University Hospital. Status: unknown.
02
Drugs
iloprost
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT03620526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03620526.